OxStem: Georg Terstappen
OxStem Limited, an Oxford-based biotech company focused on combatting age-related diseases, has revealed that its new chief scientific officer has been appointed, with Georg Terstappen stepping into the role.
Terstappen has 25 years’ of experience working in the pharmaceutical industry, most recently being located in Shanghai, China, as GlaxoSmithKline’s head of platform technologies and science in the country.
This stint at the company followed a previous five-year period with the company from 1997 to 2002, when he worked as director of systems research. Alongside this experience, he had periods working for AbbVie and Bayer.
Michael Stein, chairman and CEO of OxStem, commented: “On behalf of the entire company, I warmly welcome Georg to OxStem and we are thrilled to have attracted such an accomplished Drug Hunter to the OxStem Team. Georg brings extensive R&D management experience to OxStem and his track record of delivery in both pharma and biotech is well-evidenced. He joins OxStem at a time of significant growth and acceleration in our discovery programmes and we look forward to working with Georg on our important mission to deliver innovative medicines based on the translation of our breakthrough science.”